Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease

Chansik An,Youn Ah Choi,Dongil Choi,Yong Han Paik,Sang Hoon Ahn,Myeong-Jin Kim,Seung Woon Paik,Kwang-Hyub Han,Mi-Suk Park
DOI: https://doi.org/10.3350/cmh.2015.21.3.279
2015-01-01
Clinical and Molecular Hepatology
Abstract:BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate.METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients.RESULTS: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234).CONCLUSIONS: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC.
gastroenterology & hepatology
What problem does this paper attempt to address?